Meeting
2023 ASCO Annual Meeting
Correlation of DNA methylation signatures with response to immune checkpoint inhibitors in metastatic melanoma.
Authors
Julia Maria Ressler
Department of Dermatology, Medical University of Vienna, Vienna, Austria
Julia Maria Ressler , Erwin Tomasich , Teresa Hatziioannou , Helmut Ringl , Gerwin Heller , Rita Silmbrod , Nina Zila , Philipp Tschandl , Christoph Hoeller , Anna Sophie Berghoff , Matthias Preusser
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9561)
DOI
10.1200/JCO.2023.41.16_suppl.9561
Abstract #
9561
Poster Bd #
324
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.
First Author: Tamara A. Sussman
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain